Suraksha Diagnostic LimitedPharmaceuticals & HealthcareSURAKSHA
Q1 FY27 concall · earnings callSuraksha Diagnostic Limited
Suraksha delivered strong financial performance in Q1 with a 40% PAT growth, successful network expansion, and significant progress in its genomics vertical.
Numbers
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Total Income | ₹88.7 Cr | 21% | |
| EBITDA | ₹31.5 Cr | 28% | |
| EBITDA Margin | 36% | 2 p.p. | |
| PAT | ₹12.8 Cr | 40% | |
| PAT Margin | 14.7% | — | |
| Patients Served | 0.38 million | — | |
| Tests Performed | 2.10 million | — | |
| Revenue Per Patient | INR 2,321 | — |
Financials
From filed quarterly results. YoY and QoQ compare each metric on the same accounting basis.
| Quarter | Revenue | Net profit (PAT) | Basic EPS |
|---|---|---|---|
| Q3 FY25 | ₹59.51 Cr— YoY-10.8% QoQ | ₹5.98 Cr— YoY-41.1% QoQ | ₹1.18— YoY-39.2% QoQ |
| Q2 FY25 | ₹66.75 Cr— YoY— QoQ | ₹10.16 Cr— YoY— QoQ | ₹1.94— YoY— QoQ |
TL;DR
- Revenue grew 21% YoY to INR 887 million.
- EBITDA grew 28% YoY, with margin expanding to 36%.
- PAT grew 40% YoY to INR 128 million.
- Genomics revenue grew 136% YoY to Rs. 13.7 million.
- Network expanded with one hub and three spoke centers in Q1.
- Centres under 2 years old turned profitable with a 6.5% EBITDA margin.
Said on the call
“We are indeed pleased to report a very strong start to FY '27 with continued progress across financial performance, clinical capabilities and our strategic initiatives.”
From the Q&A
| Topic | What management said |
|---|---|
| Margin Outlook | Management expects overall EBITDA margin for FY27 to not go below 34% and mature centre margins (40.9% in Q1) to be sustainable. |
| Genomics Growth | Genomics revenue grew 136% YoY and is expected to see strong continued growth with no major CapEx needed in the next 2-3 years; current split is 80% B2C and 20% B2B. |
| Expansion Plans | The company is on track to open 100 centres by FY28; plans to add 4 hubs and 7 spokes in total for FY27 (3 hubs and 6 spokes already opened in July/August). |
| Capex and Centre Economics | Full-year Capex expected to be around Rs. 70-80 crores; a hub costs Rs. 10-10.5 crores and a spoke Rs. 1.5-2 crores; a spoke centre reaches centre-level break-even in 3-4 months. |
| Mature Centre Growth | Mature centres (over 2 years) showed 12.3-12.5% YoY growth, partly due to genomics contribution; new centres (under 2 years) turned profitable with 6.5% EBITDA margin. |
| Geographic Expansion | Expansion is now beyond West Bengal with a hub in Jharkhand and plans for Tripura; future additions will be roughly 50-50 between core and new territories. |
| Market Share | Management states Suraksha is the largest organized diagnostic player in East India, where the organized sector share is lower than the national average. |
Guidance
- Overall EBITDA margin for FY27 expected to not go below 34%.
- On track to open 100 centres by FY28.
- Capex for the year expected around Rs. 70-80 crores.
- Expect quarterly growth of around 20-odd percent for the financial year.
Source
Summary written from the transcript filed by Suraksha Diagnostic Limited for the call held on 13 Aug 2026; published 18 Aug 2026, 21:20 IST.
More Q1 FY27 concalls ·How verification works ·Report an error